ARVN Technical Analysis & Stock Price Forecast
This article provides a technical analysis of Arvinas Inc (ARVN), indicating a "Sell" consensus based on various indicators. It details the company's moving averages, momentum indicators like RSI and MACD, and identifies key support and resistance levels. The analysis highlights that while some individual moving averages show "Buy" signals, the overall technical sentiment points towards a "Sell" for ARVN.
Arvinas (ARVN) Moves 6.9% Higher: Will This Strength Last?
Arvinas (ARVN) shares jumped 6.9% following positive investor expectations for its pipeline, specifically encouraging data from an early-stage study of ARV-102 for Parkinson's disease. Despite this, the company faces negative earnings estimate revisions for the upcoming quarter, with expected losses and a significant drop in revenue. The stock currently holds a Zacks Rank #3 (Hold), prompting a watchful eye on whether its recent gain can be sustained.
Arvinas (NASDAQ:ARVN) Shares Down 5.1% - Time to Sell?
Arvinas (NASDAQ:ARVN) shares dropped 5.1% after reporting a significant earnings and revenue miss for Q4, with EPS at ($1.10) against an estimated ($0.55) and revenue of $9.5M versus $37.26M consensus. Despite analyst price target increases and several "Buy" ratings, the stock holds a mixed "Hold" consensus due to the substantial revenue decline. Insider selling and institutional ownership percentages are also detailed.
Arvinas (ARVN) Rises 6.9%: Can This Momentum Be Sustained?
Shares of Arvinas, Inc. (ARVN) recently surged 6.9% due to investor optimism over promising early-phase trial results for ARV-102, a Parkinsons' disease treatment candidate. Despite this positive momentum, the company faces projected quarterly losses and a significant decline in revenue expectations, and its consensus EPS estimates have been lowered. The stock currently holds a Zacks Rank #3 (Hold).
Arvinas (ARVN) Rises 6.9%: Can This Momentum Be Sustained?
Shares of Arvinas, Inc. (ARVN) recently surged 6.9% due to investor optimism following positive early-phase trial results for ARV-102, a Parkinson's disease treatment candidate. Despite the recent stock increase, the company faces a projected quarterly loss and a significant revenue drop year-over-year, alongside recent downward revisions in EPS estimates. Investors are advised to monitor the stock, which currently holds a Zacks Rank #3 (Hold).
Arvinas (ARVN) price target increased by 13.60% to 15.54
This article indicates that the price target for Arvinas (ARVN) has been raised by 13.60%, bringing it to $15.54. No other details about the company or the reasons for the price target increase are available in the provided content.
Arvinas (ARVN) price target increased by 13.60% to 15.54
This article reports that the price target for Arvinas (ARVN) has been increased by 13.60%, bringing it to $15.54. This update indicates a revised outlook on the stock's potential value.
Vanguard realignment leaves Arvinas (ARVN) ownership listed as 0 shares
The Vanguard Group filed an amended Schedule 13G/A, reporting 0 shares of Arvinas Inc. (ARVN) common stock due to an internal realignment effective January 12, 2026. This change means certain Vanguard subsidiaries will now report beneficial ownership separately, as explained by SEC Release No. 34-39538. The filing is administrative and does not indicate a sale of shares by Vanguard, but rather a change in reporting structure.
Arvinas (Nasdaq:ARVN) - Stock Analysis
This report provides a stock analysis for Arvinas (Nasdaq:ARVN), a clinical-stage biotechnology company. It details Arvinas's market cap, current share price, analyst consensus targets, and fundamental analysis including valuation, future growth, and financial health. The article also highlights risks such as expected earnings decline, insider selling, and current unprofitability, while noting potential in targeted therapies and recent positive clinical data.
Arvinas, Inc. (NASDAQ:ARVN) Receives Average Rating of "Hold" from Analysts
Arvinas, Inc. (NASDAQ:ARVN) has received an average "Hold" rating from nineteen research firms, with a consensus 12-month price target of $13.88. The company recently missed quarterly earnings estimates, reporting ($1.10) EPS and $9.5 million in revenue, an 84% year-over-year decline. Insider activity shows a director buying 20,000 shares, while institutional investors now own about 95.19% of the company's stock.
ARVN PE Ratio & Valuation, Is ARVN Overvalued
Arvinas Inc (ARVN) is currently considered undervalued, with a forward PS ratio of 6.97 compared to its five-year average of 82.85. The fair price for ARVN is estimated to be between $53.19 and $93.68, significantly higher than its current trading price of $10.94. Despite this undervaluation based on historical metrics, ARVN's P/S ratio of 6.97 is still considered disproportionately high relative to the industry average of 140.09 given its revenue growth of -83.95%, suggesting that this premium may be unsustainable.
H.C. Wainwright reiterates Arvinas stock rating on trial data
H.C. Wainwright reiterated a Buy rating and an $18.00 price target for Arvinas Inc. (NASDAQ:ARVN) after the company presented positive data from its Phase 1 trial of ARV-102 for Parkinson’s disease. Other firms also weighed in, with BTIG raising its price target to $16 and Piper Sandler maintaining an Overweight rating with a $20 target, while Truist Securities maintained a Hold rating. Arvinas also has ongoing collaborations and trials for other drugs, including vepdegestrant with Pfizer and luxdegalutamide with Novartis.
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), HOYA (OtherHOCPF) and TransMedics Group (TMDX)
Analysts from Citi, J.P. Morgan, and Needham have issued bullish ratings for Arvinas Holding Company (ARVN), HOYA (HOCPF), and TransMedics Group (TMDX) respectively. Citi's Yigal Nochomovitz maintained a Buy rating for Arvinas with a $21.00 price target, highlighting a 39.1% upside. J.P. Morgan's Mio Shikanai gave HOYA a Buy rating with a Yen30000.00 price target, suggesting a 7.4% upside, while Needham's Michael Matson set a Buy rating and $174.00 price target for TransMedics Group, indicating a 29.5% upside from current levels.
Arvinas’ chief medical officer Berkowitz sells $71k in shares By Investing.com
Arvinas' Chief Medical Officer, Noah Berkowitz, sold 6,435 shares of common stock for $71,431 to cover tax obligations from vested restricted stock units. This transaction, executed automatically, reduced his direct ownership to 202,503 shares. Despite a recent stock dip, shares have gained 49% over six months, and InvestingPro analysis suggests Arvinas is currently undervalued.
Arvinas’ chief medical officer Berkowitz sells $71k in shares
Arvinas' Chief Medical Officer, Noah Berkowitz, sold 6,435 shares of ARVN stock for $71,431 to cover tax obligations related to restricted stock units. This automatic sale occurred as the stock traded at $11.17, despite a 49% surge in the past six months. Recent news for Arvinas includes positive Phase 1 data for ARV-102 in Parkinson's disease, leading to varied analyst price targets and ratings.
Arvinas (ARVN) CMO reports automatic RSU tax-withholding share sale
Arvinas (ARVN) Chief Medical Officer Noah Berkowitz reported an automatic sale of 6,435 shares of common stock at $11.1004 per share. This transaction was executed on March 18, 2026, to cover tax withholding obligations associated with the vesting of his restricted stock units and was not a discretionary trade. Following the sale, Berkowitz directly holds 202,503 shares of Arvinas common stock.
Arvinas (NASDAQ:ARVN) Price Target Raised to $21.00 at Citigroup
Citigroup has raised its price target for Arvinas (NASDAQ:ARVN) to $21.00 from $18.00, maintaining a "buy" rating, indicating a potential upside of 92.75%. This comes amidst mixed analyst ratings, with a consensus "Hold" and an average target of $13.88, following a weak Q4 earnings report where Arvinas missed both EPS and revenue expectations. Despite recent insider selling by the CEO, a director purchased 20,000 shares.
Arvinas, Inc. (ARVN) reports Q4 loss, misses revenue estimates
Arvinas, Inc. reported a Q4 loss, missing revenue estimates for the period. The company's financial performance fell short of analyst expectations.
Arvinas, Inc. (ARVN) Investigation: Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Arvinas, Inc. (ARVN) securities. This investigation follows Arvinas's announcement on May 1, 2025, that it would remove certain Phase 3 trials from its development plan and reduce its workforce by approximately one-third, which caused a significant drop in its stock price. Shareholders are encouraged to contact the firm for more information about the investigation.
BTIG Analyst Raises Price Target for Arvinas (ARVN) to $16 | ARV
BTIG analyst Jeet Mukherjee has reaffirmed a 'Buy' rating for Arvinas (ARVN) and increased the price target from $14.00 to $16.00, indicating a positive outlook for the company. This follows several other analysts who have recently raised their price targets for Arvinas, a clinical-stage biotechnology company developing therapies that degrade disease-causing proteins. Wall Street analysts project an average target price of $15.24 for ARVN, suggesting a potential upside of 39.90% from its current price.
Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
Arvinas has announced positive phase 1 trial results for its investigational PROTAC degrader ARV-102 in Parkinson's disease. The drug achieved over 50% degradation of LRRK2 in cerebrospinal fluid, reduced associated biomarkers, and was well-tolerated. These findings support further development of ARV-102 for neurodegenerative conditions like Parkinson's and progressive supranuclear palsy.
BTIG raises Arvinas stock price target on positive trial data
BTIG raised its price target on Arvinas Inc. to $16 from $14, maintaining a Buy rating, following positive trial data for its LRRK2 degrader ARV-102 in Parkinson’s disease. The trial showed dose-dependent LRRK2 reductions of up to 72% and was well-tolerated. Other analysts have also adjusted their ratings and price targets, with some noting validation of Arvinas's PROTAC platform and ongoing pipeline progress.
Arvinas, Inc. (ARVN) reports Q4 loss, misses revenue estimates
Arvinas, Inc. reported a Q4 loss and missed revenue estimates. The specific financial figures for the loss and revenue are not provided in this snippet.
Arvinas reports positive Phase 1 data for Parkinson’s drug ARV-102
Arvinas Inc. announced positive Phase 1 clinical trial data for its Parkinson's disease drug, ARV-102, showing a significant reduction in LRRK2 levels in cerebrospinal fluid. The drug, which was generally well-tolerated, also reduced endolysosomal and neuroinflammatory biomarkers. Despite recent stock volatility, InvestingPro indicates the company is undervalued, with plans for a Phase 1b trial in progressive supranuclear palsy and potential registrational trials.
Arvinas (ARVN) reports positive Phase 1 ARV-102 data in Parkinson’s disease
Arvinas (ARVN) announced positive Phase 1 clinical trial data for ARV-102, an investigational PROTAC degrader for Parkinson's disease. The drug demonstrated good tolerability and achieved significant LRRK2 reduction in cerebrospinal fluid, along with reduced endolysosomal and neuroinflammatory biomarkers. Based on these results, Arvinas plans to advance ARV-102 into a Phase 1b trial for progressive supranuclear palsy in Q2 2026.
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days
Arvinas Inc. announced positive Phase 1 clinical trial data for ARV-102, an investigational PROTAC degrader for Parkinson's disease (PD). The drug demonstrated greater than 50% reduction of LRRK2 in cerebrospinal fluid (CSF) and was well tolerated across all dose levels. These results support further development of ARV-102 for neurodegenerative diseases characterized by lysosomal dysfunction, including progressive supranuclear palsy, with a Phase 1b trial in PSP planned for Q2 2026.
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing
Arvinas Inc. announced positive Phase 1 clinical trial data for ARV-102, an investigational PROTAC degrader for Parkinson's disease. The drug demonstrated over 50% reduction of LRRK2 in cerebrospinal fluid and was well-tolerated, showing potential for treating Parkinson's and progressive supranuclear palsy. The company plans to initiate a Phase 1b trial for PSP in Q2 2026, with potential for a registrational trial later in 2026.
Arvinas (ARVN) settles 6,022 RSUs; insider sold 5,685 shares
Arvinas, Inc. filed a Rule 144 notice documenting the settlement of 6,022 vested restricted stock units (RSUs) on March 18, 2026. The filing also disclosed a prior sale of 5,685 shares by Noah Berkowitz on February 13, 2026, for $67,594.65. Analysts consider these transactions routine and administrative, unlikely to be market-moving due to their modest size.
ARVN SEC Filings - Arvinas 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to Arvinas (ARVN) SEC filings, including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms. It highlights Arvinas, Inc.'s regulatory disclosures as a clinical-stage biotechnology issuer, detailing its PROTAC pipeline and specific drug candidates. The filings offer investors crucial insights into the company's financial results, corporate updates, clinical data, and regulatory milestones.
ARVN Should I Buy
Arvinas Inc. (ARVN) is presented as a "good buy" for long-term investors, despite recent price declines and some insider selling. The positive outlook is supported by insider buying, strong analyst ratings with raised price targets, and upcoming clinical data readouts. Technical analysis indicates potential for recovery, with bullish moving averages and options data showing bullish sentiment.
ARVN SEC Filings - Arvinas 10-K, 10-Q, 8-K Forms
This page provides comprehensive access to Arvinas (ARVN) SEC filings, including 10-K, 10-Q, 8-K forms, and insider trading information. It details the company's regulatory disclosures as a clinical-stage biotechnology firm focused on targeted protein degradation, highlighting updates on its PROTAC pipeline, financial results, and corporate actions. The platform also offers AI-powered tools to summarize filings and analyze key information for investors.
ARVN Should I Buy
This article analyzes Arvinas Inc. (ARVN) stock, recommending it as a good buy for beginner investors seeking a long-term strategy, despite recent price declines and some insider selling. The recommendation is based on positive insider buying, strong analyst support with raised price targets, upcoming clinical data readouts, and a bullish option sentiment. Technical indicators and financial performance (improved net income and EPS in Q4 2025, despite revenue drop) also contribute to the positive outlook.
Arvinas (ARVN) corrects CEO equity grant to 147,179 RSUs in Form 4/A
Arvinas (ARVN) has filed an amended Form 4/A to correct a clerical error in its CEO Randy Teel's equity grant. The corrected filing states that Teel was granted 147,179 Restricted Stock Units (RSUs) on February 26, 2026, not the previously reported 147,791 RSUs. These RSUs will vest in four equal annual installments starting February 12, 2027, and Teel's beneficial ownership after this adjustment now stands at 296,875 shares.
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2
Arvinas, Inc. announced that it will present Phase 1 clinical trial data for its investigational drug ARV-102 at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases. ARV-102 is an orally bioavailable PROTAC degrader targeting LRRK2, implicated in Parkinson’s disease and progressive supranuclear palsy. The presentation will cover safety, pharmacokinetic, and pharmacodynamic data.
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
Arvinas Inc. announced it will present Phase 1 clinical trial data for ARV-102, its PROTAC LRRK2 degrader for Parkinson’s disease, at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders. The presentation will detail new safety, pharmacokinetic, and pharmacodynamic information. ARV-102 is designed to cross the blood-brain barrier and target LRRK2, a protein implicated in Parkinson's and progressive supranuclear palsy.
Arvinas to present ARV-102 Parkinson’s trial data at conference
Arvinas Inc. (NASDAQ:ARVN) will present Phase 1 clinical trial data for its Parkinson's investigational drug, ARV-102, at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases in Copenhagen. The company plans to share safety, pharmacokinetic, and pharmacodynamic results for the orally bioavailable PROTAC degrader targeting LRRK2. Additionally, Arvinas intends to initiate a Phase 1b trial for ARV-102 in progressive supranuclear palsy (PSP) patients later in 2026.
Early ARV-102 Parkinson’s data to debut at Alzheimer’s-Parkinson’s conference
Arvinas (Nasdaq: ARVN) announced it will present Phase 1 human data for its oral PROTAC degrader ARV-102, targeting LRRK2, at the AD/PD 2026 conference in Copenhagen. The presentation on March 18, 2026, will cover safety, pharmacokinetics, and pharmacodynamics in Parkinson's disease patients. This continues Arvinas' strategy of providing incremental clinical data updates for its PROTAC pipeline.
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
Arvinas Inc. announced it will present Phase 1 data for its investigational drug ARV-102, a PROTAC LRRK2 degrader, at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders. The presentation will cover new safety, pharmacokinetic, and pharmacodynamic data from the clinical trial in Parkinson's disease participants. ARV-102 is designed to cross the blood-brain barrier and target LRRK2, a protein implicated in Parkinson's and progressive supranuclear palsy.
Arvinas (NASDAQ:ARVN) Sets New 12-Month High on Insider Buying Activity
Arvinas (NASDAQ:ARVN) reached a new 52-week high after Director Briggs Morrison purchased 20,000 shares for $268,000, increasing his stake by 26.31%. This insider buying activity occurred despite the company missing quarterly earnings and revenue estimates and receiving mixed analyst ratings. Arvinas focuses on biopharmaceutical therapies through its proprietary PROTAC® platform.
Arvinas Stock Pre-Market (+4.7%): Broad Biotech Rally on Geopolitical De-escalation, Falling Oil
Arvinas stock saw a pre-market increase of 4.7% as the broader biotech sector rallied. This surge is attributed to a de-escalation in geopolitical tensions and a decrease in oil prices. The article primarily reports on this stock movement and its potential causes.
Insider Buying: Briggs Morrison Acquires 20,000 Shares of Arvinas Inc (ARVN)
Briggs Morrison, a Director at Arvinas Inc (ARVN), recently purchased 20,000 shares, increasing his total holdings to 96,021 shares. This transaction is part of a larger trend of Morrison acquiring 50,000 shares over the past year, despite a higher number of insider sells for the company overall. With Arvinas Inc trading at $13.40 and an estimated GF Value of $29.80, the stock is considered a "Possible Value Trap, Think Twice."
ARVN: Multiple phase I programs advance, with key data for LRRK2 and KRAS G12D degraders expected in 2024
Arvinas, Inc. (ARVN) reported advancements in its early-stage pipeline during the Leerink Global Healthcare Conference 2026. The company highlighted promising data for LRRK2 and KRAS G12D degraders within its multiple Phase I programs. Key data readouts for these programs are anticipated in 2024, with a strategic focus on asset differentiation and clinical candidate progression.
Briggs Morrison Acquires 20,000 Shares of Arvinas (NASDAQ:ARVN) Stock
Briggs Morrison, a director at Arvinas (NASDAQ:ARVN), recently purchased 20,000 shares of the company's stock for $268,000, increasing his total holdings to 96,021 shares. This insider buying comes after the company reported a significant earnings miss, with Q4 EPS of ($1.10) against an estimated ($0.55) and an 84% year-over-year revenue decline. Analyst sentiment remains mixed, with an average "Hold" rating and a target price of $13.65 for the stock.
Piper Sandler reiterates Arvinas stock rating on platform validation
Piper Sandler has reiterated an Overweight rating and $20.00 price target on Arvinas Inc. due to the validation of its oral PROTAC platform and upcoming data readouts in 2026. The company has several key developments, including a PDUFA date for vepdegestrant, progression of luxdegalutamide to Phase II, and planned data releases for various drug candidates in Parkinson's disease, prostate cancer, and solid tumors. Despite recent financial underperformance in Q4 2025, Arvinas holds a strong cash position to fund operations into late 2028.
Discipline and Rules-Based Execution in ARVN Response
This article provides an in-depth analysis of Arvinas Inc. (NASDAQ: ARVN), highlighting strong sentiment across all horizons and an overweight bias for the stock. It details various AI-generated trading strategies—position, momentum breakout, and risk hedging—tailored for different risk profiles, along with multi-timeframe signal analysis. The report also points out an exceptional risk-reward short setup, targeting a 17.2% downside.
Arbiter Partners Capital Management LLC Invests $3.86 Million in Arvinas, Inc. $ARVN
Arbiter Partners Capital Management LLC has invested $3.86 million in Arvinas, Inc. (NASDAQ:ARVN), acquiring 452,789 shares during the 3rd quarter. This investment makes Arvinas the 10th largest position in Arbiter Partners' portfolio, representing 2.3% of their holdings and 0.71% of Arvinas's total stock. Other institutional investors have also adjusted their stakes, while analysts hold a mixed outlook on ARVN, with an average "Hold" rating and a target price of $13.47.
ARVN: Multiple phase I programs advance with key data and commercialization milestones ahead
Arvinas, Inc. (ARVN) is advancing four Phase I programs, including LRRK2 and KRAS G12D degraders, with significant data readouts anticipated in 2024 and 2026. The company's oncology and neurology pipelines are showing promising preclinical and early clinical results, supported by ongoing strategic partnerships and commercialization efforts. This update is based on an AI-generated summary of Arvinas, Inc.'s TD Cowen 46th Annual Health Care Conference Audio Transcript from March 3, 2026.
Arvinas (NASDAQ: ARVN) CEO receives large stock option and RSU grants
Arvinas, Inc. President and CEO Randy Teel received grants of 218,691 stock options and 147,791 restricted stock units (RSUs) on February 26, 2026. These equity awards, reported in a Form 4 SEC filing, vest over four years beginning February 12, 2027, contingent on his continued service. The stock options have an exercise price of $13.38, while the RSUs convert to shares for no consideration.
Arvinas (NASDAQ:ARVN) Director John Houston Sells 35,297 Shares
Arvinas Director John Houston sold 35,297 shares of ARVN stock for $466,273 on February 27th, reducing his holdings by 3.05%. This sale occurred shortly after Arvinas missed quarterly earnings expectations significantly, reporting an EPS of ($1.10) against an expected ($0.55), and revenue of $9.5M versus an anticipated $37.26M. The company currently holds a MarketBeat consensus "Hold" rating with a target price of $13.47.
Arvinas, Inc. (ARVN) Makes Significant Progress on Oncology and Neurology Trials
Arvinas Inc. (ARVN) has reported significant progress in its oncology and neurology trials, as highlighted by its Q4 and full-year 2025 financial results. The biopharmaceutical company submitted its first new drug application for a PROTAC degrader and is advancing several clinical trials, including those for KRAS G12D-mutated cancer and non-Hodgkin's lymphoma. Despite a slight decrease in annual revenue, the company continues to focus on developing novel therapies for serious diseases using its proprietary PROTAC platform.
